SCHEMBL21385686

SCHEMBL21385686

CC(C)C1Cc2ccccc2OC1c1cc(O)c(O)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.54
IGF1R P08069 1/20 0.54
HSP90AB1 P08238 4/20 0.47
BACE1 P56817 2/20 0.41
SNCA P37840 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
APEX1 P27695 1/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGS1 P23219 1/20 0.41
CNR1 P21554 1/20 0.41
RAD52 P43351 1/20 0.41
PLK1 P53350 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18655389 0.81 DYRK1A (0.57) DYRK1AIGF1RHSP90AB1BACE1SNCA
SCHEMBL18655390 0.77 BACE1 (0.67) DYRK1AHSP90AB1BACE1SNCAKDM4E
SCHEMBL30141006 0.70 DYRK1A (1.00) DYRK1AIGF1RHSP90AB1BACE1SNCA
SCHEMBL30987004 0.70 DYRK1A (1.00) DYRK1AIGF1RHSP90AB1BACE1SNCA
SCHEMBL24983851 0.70 DYRK1A (1.00) DYRK1AIGF1RHSP90AB1BACE1SNCA
SCHEMBL24984288 0.70 DYRK1A (1.00) DYRK1AIGF1RHSP90AB1BACE1SNCA
SCHEMBL30977100 0.68 ESR2 (0.51) DYRK1AIGF1RHSP90AB1PLK1
SCHEMBL30977104 0.68 ESR2 (0.51) DYRK1AIGF1RHSP90AB1PLK1
SCHEMBL16160605 0.67 KDM4E (0.74) BACE1SNCAKDM4EALDH1A1MAPT
SCHEMBL25247410 0.67 KDM4E (0.74) BACE1SNCAKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10420815-B2 Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2019-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10420815-B2 Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria NRDC, BPGM, TGM3 DYRK1A 3253/4885IGF1R 4378/4885HSP90AB1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.